RE: BIA23 Dec 2019 19:03
The China Healthcare Technology centre, which represents China’s innovative internet of things, has also been remodelled with new demonstration areas focused on oncology solutions for breast and ovarian cancer. Again, this vision centre – selling a holistic package of a healthcare pathway approach remains a healthcare model that is sold to partners, governments and healthcare systems across China. It’s a far cry from what Chinese public hospitals look like now but sells the vision well and I-campus companies will have the ability for their innovations to be showcased within it.
Conclusion
The Chinese innovation ecosystem is keen to do business with the UK and we have made sure that at a time when US China relations are cooler UK companies are well able to take advantage of the positive profile, we are able to attract. Where once the focus of Chinese partners was generic or similar drugs in recent times that ambition has changed, and China wants to be seen as a market for truly innovative therapies. I believe that our relationship with Astra Zeneca China in Wuxi, and our network experience with the key sea turtle community now provides a de-risked route for BIA members to cross the bridge, explore and partner effectively in this key market of the future. I believe it is vital for all UK biotech companies to have an Asian strategy to match their USA plan, and I look forward to helping companies deliver just that in 2020.